Willeke C. Mom-Van Roon

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Loss of astrocytic markers and impaired metabolic function in spinocerebellar ataxia type 7 patient-derived neural cultures.

Loss of astrocytic markers and impaired metabolic function in spinocerebellar ataxia type 7 patient-derived neural cultures.

Journal: Neurobiology of disease

Published: April 24, 2026

Individualized antisense oligonucleotide treatment eligibility of patients living with neurodevelopmental diseases.

Individualized antisense oligonucleotide treatment eligibility of patients living with neurodevelopmental diseases.

Journal: Cell reports. Medicine

Published: March 18, 2026

Generation of 4 human induced pluripotent stem cell lines (LUMCi070-A, -B, -C, and -D) from a patient with ischemic cerebral small vessel disease.

Generation of 4 human induced pluripotent stem cell lines (LUMCi070-A, -B, -C, and -D) from a patient with ischemic cerebral small vessel disease.

Journal: Stem cell research

Published: February 19, 2026

Impedance-based phenotypic profiling of metabotropic glutamate receptor ligand responses in SCA1 human iPSC-derived neuronal cultures.

Impedance-based phenotypic profiling of metabotropic glutamate receptor ligand responses in SCA1 human iPSC-derived neuronal cultures.

Journal: Neurobiology of disease

Published: December 17, 2025

Generation of an isogenic human induced pluripotent stem cell line for spinocerebellar ataxia type 1.

Generation of an isogenic human induced pluripotent stem cell line for spinocerebellar ataxia type 1.

Journal: Stem cell research

Published: December 12, 2025

A Novel APP p.V742L variant in a patient with ischemic small vessel disease enhances FE65 signalling.

A Novel APP p.V742L variant in a patient with ischemic small vessel disease enhances FE65 signalling.

Journal: Neurobiology of disease

Published: October 07, 2025

Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation.

Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation.

Journal: Molecular therapy. Nucleic acids

Published: July 29, 2025

Determining off-target effects of splice-switching antisense oligonucleotides using short read RNAseq in neuronally differentiated human induced pluripotent stem cells.

Determining off-target effects of splice-switching antisense oligonucleotides using short read RNAseq in neuronally differentiated human induced pluripotent stem cells.

Journal: Human molecular genetics

Published: July 02, 2025

Polyglutamine expansion induced dynamic misfolding of androgen receptor.

Polyglutamine expansion induced dynamic misfolding of androgen receptor.

Journal: Protein science : a publication of the Protein Society

Published: December 20, 2024

Mapping the glial transcriptome in Huntington's disease using snRNAseq: selective disruption of glial signatures across brain regions.

Mapping the glial transcriptome in Huntington's disease using snRNAseq: selective disruption of glial signatures across brain regions.

Journal: Acta neuropathologica communications

Published: September 26, 2024

A Guide to Chemical Considerations for the Pre-Clinical Development of Oligonucleotides.

A Guide to Chemical Considerations for the Pre-Clinical Development of Oligonucleotides.

Journal: Nucleic acid therapeutics

Published: August 07, 2024

Calcium-Enhanced Medium-Based Delivery of Splice Modulating Antisense Oligonucleotides in 2D and 3D hiPSC-Derived Neuronal Models.

Calcium-Enhanced Medium-Based Delivery of Splice Modulating Antisense Oligonucleotides in 2D and 3D hiPSC-Derived Neuronal Models.

Journal: Biomedicines

Published: July 08, 2024

Showing 1-12 of 90

Last Updated: 09/26/2026